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CytotoxicityAbstract A series of 2-aminosubstituted (5Z)-3-phenyl-5-(pyridine-2-ylmethylene)-3,5-dihydro-4
H-imidazole-4-ones (L) was prepared by the reaction of the corresponding 2-alkylthio-3,5-dihy
dro-4H-imidazole-4-ones with morpholine or piperidine in the presence of ytterbium(III) triflate.
The resulting ligands were subsequently reacted with CuCl22H2O and CoCl26H2O to give the cor-
responding copper(II) and cobalt(II) complexes, respectively. Analysis revealed that the complexes
were formed with an LMCl2 (M= Cu, Co)-type composition in all cases. The structures of the
three cobalt complexes prepared in this way were determined by X-ray crystallography. The results
revealed that the cobalt ions in these complexes were tetrahedrally coordinated to two chloride
anions and two nitrogen atoms from the pyridine and imidazole moieties of the ligand. The electro-
chemical properties of the ligands and their complexes were evaluated by cyclic voltammetry, and
the results revealed that the first stage in the reduction of the Co(II) and Cu(II) complexes involved
the reversible formation of the corresponding Co(I) and Cu(I) complexes, respectively. The cytotox-
icity activities of the organic ligands and their complexes were evaluated against several cancer cell
lines, including MCF-7, A549 and HEK293 cells. The copper complexes of the organic ligands bear-
ing a phenyl or allyl moiety at their N(3) position together with a piperidine substituent at the 2-
position of their imidazolone ring exhibited the greatest cytotoxicity of all of the compounds tested
in the current study.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).aracter-
2 O.O. Krasnovskaya et al.1. Introduction
Despite its high neuro- and nephrotoxicity, cisplatin is still one the
most commonly used anticancer drugs in clinical practice (Anderson
et al., 1990; Ries and Klastersky, 1986). In contrast to platinum, cop-
per is an endogenous metal that is necessary for normal cellular activ-
ity. For example, copper is found in several important enzymes,
including eukaryotic copper amine oxidase (Parsons et al., 1995),
NO-reductase (Gardner et al., 2002; Oshima et al., 2005) and superox-
ide dismutase (Konecny et al., 1999; Tainer and Getzoff, 1982). It is
therefore envisaged that copper complexes will be less toxic than the
corresponding platinum-based anticancer compounds (Du et al.,
2014). Bisthiosemicarbazone (Williams and Faulkner, 1996), phenan-
throline (Sharma et al., 1980; de Vizcaya-Ruiz et al., 2000) and several
other (Santini et al., 2014) copper complexes have been reported to
show high levels of cytotoxicity against numerous cancer cell lines,
and some of these complexes are currently being evaluated in clinical
trials (Kang et al., 2009; Pickart, 2008).
We recently discovered a series of cytotoxic copper complexes
based on 2-thiohydantoin derivatives, namely (5Z)-(5-pyridylmethy
lene)-2-alkylthioimidazole-4-ones (Majouga et al., 2014). These com-
plexes exhibited cytotoxic activity against several cancer cell lines,
including HEK-293 (transformed human embryonic kidney), SiHa
(cervical cancer) and MCF-7 (breast cancer) cells. It has been reported
that 2-thiohydantoin-containing complexes are one of very few classes
of copper complex that can be visualized in cell nuclei in their non-
dissociated form (Majouga et al., 2014), affording a unique opportu-
nity for the targeted delivery of cytotoxic compounds into cells. To fur-
ther investigate the structure-activity relationship of the copper
complexes of 5-pyridylmethylene-imidazole-4-ones we have synthe-
sized a series of copper complexes based on the structurally similar
2-amino-imidazole-4-ones. In contrast to our previously reported
ligands, these new systems contain a nitrogen substituent at the 2-
position of their imidazoline ring instead of a sulfur atom. We have
also prepared a series of structurally related cobalt(II) complexes of
5-pyridylmethylene-2-amino-imidazol-4-one ligands.
2. Experimental part
2.1. Materials and methods
All of the samples were prepared in reagent grade solvents. All
of the chemicals used to synthesize the ligands were obtained
from Acros or Sigma Aldrich and used as received without fur-
ther purification. All of the reactions were monitored by thin-
layer chromatography on Silufol precoated silica gel plates
(with fluorescence indicator UV254) using a 1:1 (v/v) mixture
of ethyl acetate and n-hexane as the solvent system. Melting
point (mp) data were obtained in open capillaries on an
SMP11 Stuart melting point apparatus and are uncorrected.
Elemental analyses were conducted on a Vario MICRO cube
CHNS/O Elementar system (Vario). 1H and 13C NMR spectra
were recorded on a Bruker Avance 400 (400 MHz) spectrome-
ter using CDCl3 or (CD3)2SO as a solvent. NMR data have
been reported in the following order: chemical shift (d) value
in ppm relative to the solvent resonance, which was used as
an internal reference standard; and coupling constant (J) in
Hertz (Hz). X-ray diffraction analysis was conducted on a
CAD4 diffractometer at 293 K (graphite monochromated
radiation, k(MoKa) = 0.71073 A˚, x/1.33h scan type). The
2-methylthio-imidazole-4-one starting materials were synthe-
sized according to previously published methods from the lit-
erature (Beloglazkina et al., 2005a,b; Majouga et al., 2004a,
b; Majouga et al., 2014; Mironov et al., 2013).Please cite this article in press as: Krasnovskaya, O.O. et al., Novel 2-aminoimidazo
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potentiostat in MeCN. A 0.05 M solution of Bu4NClO4 in
MeCN was used as a supporting electrolyte, with Ag/AgCl/
KCl (saturated) as a reference electrode. All of these measure-
ments were conducted under an atmosphere of argon. The
samples were dissolved in previously de-aerated solvents.
2.2. Morpholine-substituted ligands
2.2.1. General procedure
Morpholine (2 ml) and a catalytic amount of ytterbium(III)
triflate (5 mol%) were added to 3-substituted-5-((Z)-2-pyridyl
methylene)-2-methylthioimidazole-4-one. The reaction mix-
ture was boiled until none of reagents were observed by
TLC. The reaction mixture was evaporated to dryness, then
EtOH (1 ml) was added and the obtained precipitate was fil-
tered off and recrystallized from ethanol.
2.2.1.1. (5Z)-3-phenyl-2-(morpholine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one (1). The reac-
tion of 0.207 g (0.7 mmol) (5Z)-3-phenyl-5-(2-pyridylmethy
lene)-2-methylthiotetrahydro-4H-imidazole-4-one with mor-
pholine yielded 0.118 g (50%) of compound 1. M. p. 223 C.
1H NMR (CDCl3): 8.78 (s, 1H, Ha-Py), 8.64 (d, 1H,
J= 8.8 Hz, Hb-Py), 7.80 (t, 1H, J= 8.0 Hz, Hc-Py), 7.56–
7.42 (m, 5H, Ph), 7.23 (t, 1H, J= 6.4 Hz, Hb-Py), 7.00 (s,
1H, HC‚), 3.90 (s, 4H, CH2OCH2), 3.70 (m, 4H, CH2NCH2).
IR (cm1): 1730 (C‚O), 1630 (C‚N), 1590 (C‚C). Elemen-
tal analysis: C19H18N4O2 calculated: C 68.26%, H 5.38%, N
16.76%; found: C 68.30%, H 5.49%, N 16.48%.
2.2.1.2. (5Z)-3-methyl-2-(morpholine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one (2). The reac-
tion of 0.2 g (0.86 mmol) (5Z)-3-methyl-5-(2-pyridylmethy
lene)-2-methylthiotetrahydro-4H-imidazole-4-one with mor-
pholine yielded 0.150 g (64%) of compound 2. M. p. 155 C.
1H NMR (CDCl3): 8.82 (s, 1H, Ha-Py), 8.58 (d, 1H,
J= 7.2 Hz, Hb-Py), 7.80 (t, 1H, J= 6.4 Hz, Hc-Py), 7.23 (t,
1H, J= 5.2 Hz, Hb-Py), 6.93 (s, 1H, HC‚), 3.89 (s, 4H, CH2-
OCH2), 3.73 (s, 4H, CH2NCH2), 3.30 (s, 3H, NCH3). IR
(cm1): 1720(C‚O), 1640 (C‚N), 1600 (C‚C). Elemental
analysis: C14H16N4O2 calculated: C 61.76%, H 5.88%, N
20.59%; found: C 61.65%, H 5.86%, N 20.64%.
2.2.1.3. (5Z)-3-allyl-2-(morpholine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one (3). The reac-
tion of 0.133 g (0.52 mmol) (5Z)-3-allyl-5-(2-pyridylmethy
lene)-2-methylthiotetrahydro-4H-imidazole-4-one with mor-
pholine yielded 0.11 g (71%) of compound 3. M. p. 148 C.
1H NMR (CDCl3): 8.82 (s, 1H, Ha-Py), 8.57 (s, 1H, Hb-Py),
7.80 (s, 1H, Hc-Py), 7.22 (s, 1H, Hb-Py), 6.94 (s, 1H, HC‚),
5.93 (m, 1H, HC‚), 5.27 (m, 2H, H2C‚), 4.34 (m, 2H,
CH2), 3.86 (m, 4H, CH2OCH2), 3.73 (s, 4H, CH2NCH2). IR
(cm1): 1740 (C‚O), 1630 (C‚N), 1660 (C‚C), 1600
(C‚C). Elemental analysis: C16H18N4O2 calculated: C
64.43%, H 6.04%, N 18.79%; found: C 64.11%, H 6.08%,
N 18.61%.
2.2.1.4. (5Z)-3-(2-azidoethyl)-2-(morpholine-1-yl)-5-(pyri-
dine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (4). The
reaction of 0.2 g (0.86 mmol) (5Z)-3-azidoethyl-5-(2-pyridylmele-4-one complexes of copper(II) and cobalt(II): Synthesis, structural character-
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morpholine yielded 0.202 g (46%) of compound 4. 1H NMR
(CDCl3): 8.67 (d, 1H, J= 8.0 Hz, Ha-Py), 8.64 (dt, 1H,
J1 = 4.8 Hz, J2 = 0.8 Hz, Hb-Py), 7.72 (dt, 1H,
J1 = 7.91 Hz, J2 = 1.82 Hz, Hc-Py), 7.18–7.14 (m, 1H, Hb-
Py), 6.99 (s, 1H, HC‚), 3.91–3.85 (m, 4H, CH2OCH2), 3.81
(dd, 2H, J1 = 9.13 Hz, J2 = 3.2 Hz, CH2N3), 3.73 (t, 2H,
J= 5.7 Hz, CH2CH2N3), 3.66–3.61 (m, 4H, CH2NCH2). IR
(cm1): 2114 (N3), 1718 (C‚O), 1639 (C‚C). Elemental anal-
ysis: C15H17N7O2 calculated: C 55.04%, H 5.23%, N 29.95%;
found: C 54.90%, H 5.28%, N 29.91%.
2.3. Piperidine-substituted ligands
2.3.1. General procedure
Piperidine (4.3 ml) and a catalytic amount of ytterbium(III)
triflate (5 mol%) were added to 3-substituted (5Z)-(5-pyridyl
methylene)-2-methylthio-imidazole-4-one. The reaction mix-
ture was boiled until none of starting reagents was seen on
TLC. The reaction mixture was evaporated to dryness, then
diethyl ether was added and the obtained precipitate was fil-
tered off and recrystallized from ethanol.
2.3.1.1. (5Z)-3-phenyl-2-(piperidine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one (5). The reac-
tion of 0.2 g (0.86 mmol) (5Z)-3-phenyl-5-(2-pyridylmethy
lene)-2-methylthiotetrahydro-4H-imidazole-4-one with piperi-
dine yielded 0.202 g (71%) of compound 5. M. p. 220 C. 1H
NMR (CDCl3): 8.68 (m, 2H, Ha-Py + Hb-Py), 7.77 (t, 1H,
J= 8.2 Hz, Hc-Py), 7.53–7.47 (m, 5H, Ph), 7.16 (t, 1H,
J= 6.0 Hz, Hb-Py), 6,94 (s, 1H, HC‚), 3.39 (m, 4H, CH2-
NCH2), 1.66–1.50 (m, 6H, CH2CH2NCH2CH2CH2). Elemen-
tal analysis: C20H20N4O2 calculated: C 72.29%, H 6.02%, N
16.87%; found: C 72.61%, H 6.22%, N 16.75%.
2.3.1.2. (5Z)-3-methyl-2-(piperidine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one (6). The reaction
of 0.2 g (0.86 mmol) (5Z)-3-methyl-5-(2-pyridylmethylene)-2-m
ethylthiotetrahydro-4H-imidazole-4-onewith piperidine yielded
0.190 g (82%) of compound 6. M. p. 140 C. 1HNMR (CDCl3):
8.70 (d, 1H, J= 8.0 Hz, Ha-Py), 8,65 (d, 1H, J= 4.40 Hz, Hb-
Py), 7.73 (dt, 1H, J1 = 7.6 Hz, J2 = 1.6 Hz, Hc-Py), 7.14 (m,
1H, Hb-Py), 6.91 (s, 1H, HC‚), 3.6 (m, 4H, CH2NCH2), 3,28
(s, 3H, CH3), 1.76 (m, 6H, CH2CH2NCH2CH2CH2). IR
(cm1): 1715 (C‚O), 1627 (C‚N), 1589 (C‚C). Elemental
analysis: C15H18N4O2 calculated: C 66.67%, H 6.67%, N
20.74%; found: C 66.68%, H 6.89%, N 20.48%.
2.3.1.3. (5Z)-3-allyl-2-(piperidine-1-yl)-5-(pyridine-2-ylmethy-
lene)-3,5-dihydro-4H-imidazole-4-one (7). The reaction of
0.134 g (0.52 mmol) (5Z)-3-allyl-5-(2-pyridylmethylene)-2-met
hylthiotetrahydro-4H-imidazole-4-one with piperidine yielded
0.154 g (61%) of compound 7. M. p. 172 C. 1HNMR (CDCl3):
79 (s, 1H, Ha-Py), 8.64 (s, 1H, Hb-Py), 7.80 (s, 1H, Hc-Py),
7.20 (s, 1H, Hb-Py), 6.88 (s, 1H, HC‚), 5.94 (m, 1H, HC‚),
5.26 (m, 2H, H2C‚), 4.31 (m, 2H, CH2), 3.65 (m, 4H, CH2-
NCH2), 1.75 (m, 6H, CH2CH2NCH2CH2CH2). IR (cm
1):
1740 (C‚O), 1625 (C‚N), 1649 (C‚C), 1598 (C‚C). Ele-
mental Analysis: C17H20N4O2 calculated: C 68.92%, H
6.76%, N 18.92%; found: C 68.55%, H 6.70%, N 18.79%.Please cite this article in press as: Krasnovskaya, O.O. et al., Novel 2-aminoimidazo
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2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one (8). The reac-
tion of 0.05 g (0.17 mmol) (5Z)-3-(2-azidoethyl)-5-(2-pyridyl
methylene)-2-methylthiotetrahydro-4H-imidazole-4-one with
piperidine yielded 0.0325 g (58%) of compound 8. 1H NMR
(CDCl3): 8.71 (dt, 1H, J1 = 8.1 Hz, J2 = 0.9 Hz, Ha-Py) 8.62
(d, 1H, J= 4.8 Hz, Hb-Py), 7.71 (dt, 1H, J1 = 7.8 Hz,
J2 = 1.8 Hz, HY-Py) 7.13 (ddd, 1H, J1 = 7.4 Hz,
J2 = 4.8 Hz, J3 = 1.1 Hz, Hb-Py), 6.92 (s, 1H, HC‚), 3.80
(t, 2H, J= 6.4 Hz, CH2N3), 3.69 (t, 2H, J= 6.2 Hz, CH2),
3.55 (m, 4H, CH2NCH2), 1.76 (s, 6H, CH2CH2NCH2CH2-
CH2). IR (cm
1): 2080 (N3), 1730 (C‚O), 1660 (C‚C). Ele-
mental analysis: C16H19N7O calculated: C 59.06%, H 5.89%,
N 30.13%; found: C 59.36%, H 5.99%, N 29.81%.
2.4. Coordination compounds
To the solution of ligand 1–8 in 1 ml of CH2Cl2 the solution of
equimolar amount of CuCl22H2O or CoCl26H2O in 1 ml of
n-BuOH was carefully added and the mixture was left in a
closed vessel until precipitation. The forming dark green crys-
tals were filtered off and dried in air.
2.4.1. (5Z)-3-phenyl-2-(morpholine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II)
dichloride (1a)
Complex 1a was obtained from 10 mg (0.03 mmol) of com-
pound 1 and 5.3 mg (0.03 mmol) CuCl22H2O. Yield 3 mg
(22%). Elemental analysis: C19H18N4O2CuCl2 calculated: C
48.67%, H 3.84%, N 11.95%; found: C 48.92%, H 3.80%,
N 11.92%.
2.4.2. (5Z)-3-methyl-2-(morpholine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II)
dichloride (2a)
Complex 2a was obtained from 10 mg (0.037 mmol) of com-
pound 2 and 6.3 mg (0.037 mmol) CuCl22H2O. Yield 3 mg
(20%). Elemental analysis: C14H16N4O2CuCl2 calculated: C
41.33%, H 3.94%, N 13.78%; found: C 41.50%, H 4.15%,
N 13.56%.
2.4.3. (5Z)-3-allyl-2-(morpholine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II)
dichloride (3a)
Complex 3a was obtained from 10 mg (0.036 mmol) of com-
pound 3 and 5.7 mg (0.036 mmol) CuCl22H2O. Yield 3.9 mg
(25%). Elemental analysis: C16H18N4O2CuCl2 calculated: C
44.40%, H 4.19%, N 12.95%; found: C 44.26%, H 4.07%,
N 13.07%.
2.4.4. (5Z)-3-(2-azidoethyl)-2-(morpholine-1-yl)-5-(pyridine-
2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II)
dichloride (4a)
Complex 4a was obtained from 28.7 mg (0.092 mmol) of com-
pound 4 and 16 mg (0.092 mmol) CuCl22H2O. Yield 8.5 mg
(20%). Elemental analysis: C15H17N7O2CuCl2 calculated: C
39.01%, H 3.71%, N 21.23%; found: C 39.19%, H 3.95%,
N 21.33%.le-4-one complexes of copper(II) and cobalt(II): Synthesis, structural character-
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4 O.O. Krasnovskaya et al.2.4.5. (5Z)-3-phenyl-2-(piperidine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II)
dichloride (5a)
Complex 5a was obtained from 20 mg (0.06 mmol) of com-
pound 5 and 10.2 mg (0.059 mmol) CuCl22H2O. Yield 7 mg
(25%). Elemental analysis: C20H20N4OCuCl2 calculated: C
51.44%, H 4.29%, N 12.00%; found: C 51.60%, H 4.22%,
N 11.99%.
2.4.6. (5Z)-3-methyl-2-(piperidine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II)
dichloride (6a)
Complex 6a was obtained from 10 mg (0.037 mmol) of com-
pound 6 and 8.8 mg (0.052 mmol) CuCl22H2O. Yield 3.4 mg
(22%). Elemental analysis: C15H18N4OCuCl2 calculated: C
44.51%, H 4.48%, N 13.84%; found: C 44.39%, H 4.56%,
N 13.89%.
2.4.7. (5Z)-3-allyl-2-(piperidine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II)
dichloride (7a)
Complex 7a was obtained from 10 mg (0.034 mmol) of com-
pound 7 and 5.8 mg (0.034 mmol) CuCl22H2O. Yield 3.7 mg
(25%). Elemental analysis: C17H20N4OCuCl2 calculated: C
47.39%, H 4.65%, N 13.01%; found: C 47.32%, H 4.57%,
N 13.22%.
2.4.8. (5Z)-3-(2-azidoethyl)-2-(piperidine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one copper(II)
dichloride (8a)
Complex 8a was obtained from 16.3 mg (0.05 mmol) of com-
pound 8 and 9 mg (0.05 mmol) CuCl22H2O. Yield 4.6 mg
(20%). Elemental analysis: C16H19N2OCuCl2 calculated: C
41.79%, H 4.16%, N 21.32%; found: C 41.65%, H 4.21%,
N 21.23%.
2.4.9. (5Z)-3-phenyl-2-(morpholine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II)
dichloride (1b)
Complex 1b was obtained from 10 mg (0.03 mmol) of com-
pound 1 and 7.2 mg (0.03 mmol) CoCl26H2O. Yield 3.3 mg
(24%). Elemental analysis: C19H18N4O2CoCl2 calculated: C
49.15%, H 3.88%, N 12.08%; found: C 49.47 %, H 4.11 %,
N 12.23%.
2.4.10. (5Z)-3-methyl-2-(morpholine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II)
dichloride (2b)
Complex 2b was obtained from 10 mg (0.037 mmol) of com-
pound 2 and 8.8 mg (0.037 mmol) CoCl26H2O. Yield 3.1 mg
(21%). Elemental analysis: C14H16N4O2CoCl2 calculated: C
41.79%, H 3.98%, N 13.93%; found: C 41.60%, H 3.76%,
N 13.73%.
2.4.11. (5Z)-3-allyl-2-(morpholine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II)
dichloride (3b)
Yield 3.8 mg (24%). Complex 3b was obtained from 10 mg
(0.036 mmol) of compound 3 and 8 mg (0.036 mmol) CoCl2-
6H2O. Elemental analysis: C16H18N4O2CoCl2 calculated: CPlease cite this article in press as: Krasnovskaya, O.O. et al., Novel 2-aminoimidazo
ization and cytotoxicity. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.44.88%, H 4.24%, N 13.08%; found: C 45.11 %, H 4.40%,
N 12.99%.
2.4.12. (5Z)-3-(2-azidoethyl)-2-(morpholine-1-yl)-5-(pyridine-
2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II)
dichloride (4b)
Complex 4b was obtained from 28.7 mg (0.092 mmol) of com-
pound 4 and 21.3 mg (0.092 mmol) CoCl26H2O. Yield
10.5 mg (25%). Elemental analysis: C15H17N7O2CoCl2 calcu-
lated: C 39.41%, H 3.75%, N 21.45%; found: C 39.44%, H
3.83%, N 21.32%.
2.4.13. (5Z)-3-phenyl-2-(piperidine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II)
dichloride (5b)
Complex 5b was obtained from 10 mg (0.03 mmol) of com-
pound 5 and 7.1 mg (0.059 mmol) CoCl26H2O. Yield 3.2 mg
(24%). Elemental analysis: C20H20N4OCoCl2 calculated: C
51.96%, H 4.33%, N 12.12%; found: C 52.13%, H 4.39%,
N 11.95%.
2.4.14. (5Z)-3-methyl-2-(piperidine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II)
dichloride (6b)
Complex 6b was obtained from 10 mg (0.037 mmol) of com-
pound 6 and 12.4 mg (0.052 mmol) CoCl26H2O. Yield
3.3 mg (23%). Elemental analysis: C15H18N4OCoCl2 calcu-
lated: C 45.01%, H 4.50%, N 14.00%; found: C 44.89%, H
4.34%, N 13.88%.
2.4.15. (5Z)-3-allyl-2-(piperidine-1-yl)-5-(pyridine-2-
ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II)
dichloride (7b)
Complex 7b was obtained from 10 mg (0.034 mmol) of com-
pound 7 and 8.1 mg (0.034 mmol) CoCl26H2O. Yield 3 mg
(20%). Elemental analysis: C17H20N4OCoCl2 calculated: C
47.90%, H 4.70%, N 13.15%; found: C 48.19%, H 4.95%,
N 13.23%.
2.4.16. (5Z)-3-(2-azidoethyl)-2-(piperidine-1-yl)-5-(pyridine-
2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one cobalt(II)
dichloride (8b)
Complex 8b was obtained from 16.3 mg (0.05 mmol) of com-
pound 8 and 12 mg (0.05 mmol) CoCl26H2O. Yield 4.6 mg
(21%). Elemental analysis: C16H19N2OCoCl2 calculated: C
42.22%, H 4.21%, N 21.54%; found: C 42.29%, H 4.35%,
N 21.50%.3. Results and discussion
Herein, we report the synthesis and characterization of a series
of novel 2-aminosubstituted (5Z)-3-phenyl-5-(pyridine-2-ylme
thylene)-3,5-dihydro-4H-imidazole-4-ones and their copper
(II) and cobalt(II) complexes. These ligands varied in terms
of the structure of their amine moiety (i.e., morpholine or
piperidine), as well as the nature of the substituent on their
N(3) atom (i.e., phenyl, methyl, allyl or 2-azidoethyl). It is
noteworthy that all of these ligands contained an azide group,
making their complexes amenable to the preparation of cova-le-4-one complexes of copper(II) and cobalt(II): Synthesis, structural character-
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Novel 2-aminoimidazole-4-one complexes of copper(II) and cobalt(II) 5lent conjugates with both low molecular weight compounds
and biopolymers using ‘‘click” chemistry.
3.1. Synthesis and characterization
The most commonly used approach for the synthesis to
2-amino-imidazole-4-ones involves the reaction of
2-thiohydantoins or their S-alkylated derivatives with an
amine under heating (El-Barbary et al., 2000; Hu et al.,
2002) or microwave irradiation (Asmaa et al., 2007). It is note-
worthy that S-alkylated thiohydantoins have been reported to
show better results in these reactions than 2-thiohydantoins
(Carver et al., 1997; Grimmet, 1970; Lindel and Hoffmann,
1997; Roue and Bergman, 1999; Ybrahim et al., 1980). With
this in mind, S-alkylated thiohydantoins were selected as
starting materials for this study.
We initially investigated the reactions of 2-methylthio-
substituted imidazolones with morpholine under reflux condi-
tions. However, these conditions failed to afford the desired 2-
morpholyl-substituted imidazolones 5–7 in yields greater than
10%. To increase the yields of the target amino-imidazolones
we investigated the use of several Lewis acid catalysts, includ-
ing AlCl3, ZnCl2 and Yb(OTf)3. The results revealed that
AlCl3 and ZnCl2 did not catalyze the reaction, whereas the
use of ytterbium(III) triflate led to a significant increase in
the yields of the desired amino-substituted imidazolones to
46–82% (Scheme 1).
Compounds 3–6 were isolated as single geometric isomers,
which were determined to the (Z)-isomers based on the chem-
ical shifts and the coupling constants of the vinylic protons by
1H NMR spectroscopy (Mironov et al., 2013). The (Z)-
configurations of ligands 2, 5 and 6 were also confirmed based
on the X-ray diffraction analysis of the corresponding coordi-
nation complexes 2b, 5b and 6b (see below).
A series of Cu(II) and Co(II) complexes were prepared
using the (5Z)-2-amino-5-(pyridine-2-ylmethylene)-3,5-dihy
dro-4H-imidazole-4-ones prepared in the current study by
the direct reaction of CH2Cl2 solutions of these ligands with
copper(II) or cobalt(II) chloride, respectively (Scheme 2). All
of the resulting complexes were characterized by elemental
analysis. The coordination compounds 1a–6a, 1b, 2b, 4b, 7b
and 8b were also characterized by UV/Vis spectroscopy. Char-
acteristic low-intensity d–d transition bands were observed in
the UV/Vis spectra of all of the coordination compounds pre-Scheme 1 Synthesis of (5Z)-2-amino-5-(pyridine-2-y
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and Supplementary information). These data were consistent
with the literature data for the tetrahedral Cu(II) and Co(II)
complexes of 2-substituted 5-pyridylmethylene-imidazol-4-on
es (Beloglazkina et al., 2005a,b, 2006a,b; Majouga et al.,
2004a,b, 2009, 2014). According to the literature (Guo et al.,
2002; Rowland et al., 2000; Hennig et al., 1995, and previous
references), the UV/Vis spectra of square planar copper(II)
complexes should contain a broad band in the range of 550–
750 nm, which would show a bathochromic shift upon tetrahe-
dral distortion. The UV/Vis spectra of square planar cobalt
complexes normally contain only one band in the visible
region, whereas tetrahedral Co(II) complexes generally give
three bands (or a broad band, representing the superposition
of two overlapping bands) in this region (Van der Bergen
et al., 1974; Beloglazkina et al., 2013). All of the complexes
prepared in the current study also exhibited strong charge
transfer bands in the UV region of their electronic spectra
(see Supplementary information).3.2. Molecular structures of complexes 2b, 5b and 6d
The structures of complexes 2b, 5b and 6b were confirmed by
X-ray diffraction analysis, and the crystal structures are shown
in Fig. 2. Selected bond lengths and bond angles from these
crystal structures are shown in Tables 1 and 2. The previously
reported (Majouga et al., 2004a,b) crystal structure of the
cobalt complex of (5Z)-3-phenyl-2-methylthio-5-(pyridine-2-y
lmethylene)-3,5-dihydro-4H-imidazole-4-one (complex A) is
also shown in Fig. 1 for the sake of comparison. All of the
crystallographic data and refinement parameters are shown
in Tables S1, together with a list of bond lengths and bond
angles. The cobalt ions in all of these complexes were tetrahe-
drally coordinated to the two nitrogen atoms of the pyridine
and thiohydantoin rings and two chloride anions. The cobalt
atoms were located in a distorted tetrahedral environment with
CoAN distances of 2.032–2.040(10) Ǻ (CoANPy) and 1.989–
1.997(10) Ǻ (CoANIm), which were similar to those observed
in complex A (Majouga et al., 2004a,b). The phenyl substituent
at the N(3) position of the ligand moiety in complex 5b was
near perpendicular to the plane of the imidazolone ring. The
piperidine and morpholine rings were found to exist in the
chair conformations.lmethylene)-3,5-dihydro-4H-imidazole-4-ones 1–8.
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Scheme 2 Synthesis of copper(II) and cobalt(II) complexes of 2-amino-imidazole-4-ones 1–8.
Figure 1 Electronic spectra of cobalt(II) complexes 2b, 4b, 5b, 7b
and 8b, 550–800 nm (DMSO, 104 M).
6 O.O. Krasnovskaya et al.Consideration of the data in Tables 1 and 2 revealed that
while the differences in the CoAN and CoACl bond lengths
of the complexes of the 2-amino- and 2-thio-substituted
imidazole-4-ones were negligible, the Cl1ACoAN2 bond
angles differed considerable in these complexes. The tetrahe-
dral coordination environment of the cobalt ions in the
amino-substituted ligand complexes (2b, 5b, 6b) underwent
much less distortion than the corresponding sulfur-Figure 2 Molecular structures of coordination compounds 2b, 5b, 6
methylthio-5-(pyridine-2-ylmethylene)-3,5-dihydro-4H-imidazole-4-one
shown on blue, nitrogen atoms in light blue, chlorine atoms in green,
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higher level of steric hindrance around the metal ion of the
2-methylthio substituent compared with the corresponding
2-amino group.
3.3. Electrochemistry
Electrochemical studies were conducted using ligands 1, 2 and
7, together with their complexes, as representative examples by
cyclic voltammetry (CV) using glassy carbon, platinum and
gold electrodes. The results showed that all three of the ligands
were reduced in two steps, the first of which was reversible with
the second being irreversible (see Fig. 3 and Table 3). Ligand 1
bearing a phenyl substituent on its N(3) atom was reduced
much more readily (i.e., 200 mV less cathodic) than the corre-
sponding methyl- and allyl-substituted ligands 2 and 7, most
likely because of the presence of the conjugated phenyl
fragment.
The oxidation reactions of compounds 1, 2 and 7 revealed
that ligand 1 was irreversibly oxidized in a single-electron pro-
cess, whereas compounds 2 and 7 were irreversibly oxidized in
a two-electron process (Table 3, Fig. 3).
The cyclic voltammograms for cobalt complexes 1b and 2b
contained additional peaks in the cathodic region for Epc val-
ues in the range of 0.89 to 1.0 V for all of the electrodes,
corresponding to the reduction of Co(II) to Co(I) (Table 3,b in comparison with the molecular structure of (5Z)-3-phenyl-2-
cobalt(II) dichloride A (Majouga et al., 2004a,b). Cobalt ions are
oxygen atoms in red, and sulfur atom in yellow.
le-4-one complexes of copper(II) and cobalt(II): Synthesis, structural character-
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Table 1 Selected bond lengths for coordination compounds
2b, 5b, 6b and Co(II) complex A (Majouga et al., 2004a,b).
Compound CoACl1 CoACl2 CoAN(Py) CoAN(Im)
2b 2.231(2) 2.240(2) 2.040(4) 1.992(3)
5b 2.235(1) 2.245(1) 2.036(3) 1.997(3)
6b 2.237(1) 2.226(1) 2.032(4) 1.989(3)
A 2.231(2) 2.240(2) 2.031(2) 1.9262(19)
Novel 2-aminoimidazole-4-one complexes of copper(II) and cobalt(II) 7Fig. 4). The initial reduction of the cobalt complexes was
found to be reversible at all of the electrodes. However, the
intensity of the Co(II)/Co(I) re-oxidation peak for complex
2b was equal to about half of the reduction current over the
Au and Pt electrodes. This result therefore suggested that the
Co(I)-containing intermediates were stable on the timescale
required for their analysis by CV, and that they were less stable
on metal electrodes than the GC electrode.
The other peaks observed in the cathode region for the Co
complexes were attributed to the reduction of the ligand frag-
ments. These peaks were shifted slightly for complexes 2b and
7b relative to the corresponding peaks of the ligand, with the
shift for complex 1b being the greatest of all (approximately
200 mV). These results indicate that the complexation of the
ligands with cobalt leads to a change in the mechanism with
which the ligand moiety is oxidized. This was confirmed by
the fact that the first anodic peak for the complexes was a
two-electron process.
The copper-containing complexes 1a–3a were reversibly
reduced at potentials (Epc) in the range of 0.24–0.26 V (i.e.,
potentials around 200 mV). These potentials were less cathodic
than those previously reported by our group for the thiohy-
dantoin complexes of copper(II), which showed an Epc value
of 0.45 V (Beloglazkina et al., 2005a).
The cyclic voltammograms showed that there were no des-
orption peaks corresponding to zero-valent copper on the GC
or Pt electrodes, even under the reverse potential scan condi-
tions after the oxidation and reduction of the ligand fragments.
This result therefore indicated that the Cu(I)-containing inter-
mediates were stable as complexes with both negatively and
positively charged ligands. However, sharp triangular peaks
(without a diffusion loop) were observed at the Au electrode
for the copper-containing complexes 1a and 2a after the oxida-
tion or reduction of the ligand moiety (Fig. 5), which were
characteristic for the desorption of metallic copper from the
electrode surface. It is therefore possible that the reduction
intermediates (i.e., complexes of the negatively charged ligand
(L) with Cu(I)) could be unstable and disproportionate to
give Cu(II) and Cu(0) complexes, with the latter of these two
complexes decomposing with the release of metallic copper:Table 2 Selected angles for coordination compounds 2b, 5b, 6b an
Compound Cl1ACoACl2 Cl1-ACoAN1 Cl1ACoA
2b 111.25(6) 114.6(1) 112.1(1)
5b 113.94(5) 110.1(1) 109.00(9)
6b 113.82(5) 108.1(1) 116.7(1)
A 111.43(7) 105.71(17) 120.18(14
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In contrast, any complexes formed with the positively
charged ligands would be oxidized because of the low donor
ability of the cationic ligand fragments.
It is noteworthy that no desorption peaks were observed for
cycling potentials in the range of 0.1–0.65 V, which indicated
the cobalt(I) complex formed with the neutral ligand was
stable under these conditions.
3.4. Cytotoxicity
The ligands and the corresponding copper and cobalt com-
plexes prepared in the current study were tested in terms of
their in vitro cytotoxicity against cell cancer cells lines, includ-
ing human lung cancer (A549), breast adenocarcinoma (MCF-
7) and human embryonic kidney (HEK293) cells using a stan-
dard MTT assay (Mosmann, 1983). The results of this assay
are shown in Table 4 together with the results obtained for
the clinically used drugs cisplatin and doxorubicin, which have
been included for comparison.
The coordination of a metal ion was found to be essential
for the cytotoxicity of the test compounds. For example, the
IC50 values of the free ligands were much higher than those
of the corresponding copper complexes. However, the cytotox-
icities of the cobalt complexes were substantially lower than
those of the corresponding copper complexes, although in
some cases they were higher than those of the free ligands.
The nature of the amine substituent at the 2 position of the
imidazolone ring was also found to be important to the cyto-
toxicity of these compounds. For example, compounds con-
taining a piperidine substituent (i.e., 5–7) were generally 1.5–
2 times more active than compounds containing a morpholine
residue at the same position (i.e., 1–3). The nature of the sub-
stituent at the N(3) position of the imidazolone ring also had a
considerable impact on the cytotoxicity, which increased in the
order Ph > Allyl > Me. This increase in the cytotoxicity
correlates well with the increasing lipophilicity of the
complexes.
HEK293 cells were found to be the most vulnerable of all
the cell lines tested in the current study toward the test com-
pounds, with complex 5a showing the greatest cytotoxicity of
all of the test complexes. Furthermore, the cytotoxicity of com-
plex 5a toward HEK293 cells was similar to that of cisplatin.
The most active cobalt complexes were found to be com-
pounds 1b and 7b. The cytotoxicities of these complexes
toward MCF7 cells were 1.5 times greater than those of
cisplatin.
Although the generation of reactive oxygen species (ROS)
has been cited as a major contributory factor to the high tox-d Co(II) complex A (Majouga et al., 2004a,b).
N2 Cl2ACoAN1 Cl2ACoAN2 N1ACoAN2
101.4(1) 120.1(1) 96.1(2)
102.1(1) 122.76(9) 96.6(1)
104.5(1) 114.9(1) 96.3(1)
) 105.75(11) 114.34(14) 96.81(18)
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Table 3 Electrochemical reduction (ERed) and oxidation (EOx) potentials of ligands and complexes, measured relatively to Ag|AgCl|
KCl (sat.) by cyclic voltammetry (Ep is the peak potential) at glassy carbon, Pt, and Au electrodes. DMF, 0.1 M Bu4NClO4, 200 mV/s.
The values after the slash marks represent the peak potentials for the reverse CV scans.
Compound Electrode EpRed, V EpOx, V
1 Au 1.33/1.26
1.84/0.55
1.39
GC 1.37/1.28
1.87/0.57
1.35
Pt 1.37/1.25 1.38
2 Au 1.55/1.48
2.00/0.78
1.14
1.58
GC 1.60/1.48
2.12/0.75
1.14
1.51
Pt 1.60/1.48 1.16
1.27
7 Au 1.47/1.40
1.97/0.70
1.23
1.64
GC 1.46/1.36
2.04/0.64
1.26
1.59
Pt 1.52/1.42 1.19
1a Au 0.25/0.42
1.54/1.47
2.01
1.08
1.17
GC 0.15/0.24
1.54
2.10
1.21
Pt 0.18/0.59
1.56
1.24
1b Au 0.96/0.89
1.51/1.36
2.01
1.09
1.23
GC 0.98/0.91
1.52/1.39
2.01
1.23
Pt 0.96/0.90
1.62
1.30
2a Au 0.24/0.37
1.59
1.84
1.12
1.27
GC 0.15/0.22
1.62
2.01
1.10
Pt 0.17/0.37
1.60
1.23
2b Au 0.98/0.90
1.55/1.44
1.06
1.15
1.31
GC 0.99/0.92
1.58
1.21
Pt 1.00/0.91
1.61
1.26
7a Au 0.26/0.41
1.51/1.38
1.19
1.30
GC 0.24/0.48
1.58
1.20
Pt 0.24/0.40
1.53
1.23
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Table 3 (continued)
Compound Electrode EpRed, V EpOx, V
7b Au 0.90/0.84
1.47/1.35
1.13
1.26
GC 0.89/0.80
1.48
1.21
Pt 0.92/0.85
1.50/1.36
1.26
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Figure 3 CVA for ligands 1 and 2 (103 M, DMF, Bu4NClO4) on Au electrode.
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Figure 4 CVA for cobalt complexes 1b and 2b (103 M, DMF, Bu4NClO4) on Au electrode.
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(Hajrezaie et al., 2014; Mookerjee et al., 2006; Ng et al.,
2014; Guo et al., 2010; Maheswari et al., 2008), we have
assumed that the compounds described in this study do not
induce the generation of ROS. This suggestion is supported
by the lack of a correlation between the reduction potentialsPlease cite this article in press as: Krasnovskaya, O.O. et al., Novel 2-aminoimidazo
ization and cytotoxicity. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.of these compounds and their cytotoxicity. All of the com-
plexes prepared in the current study showed relatively low
reduction potentials compared with those reported in our pre-
vious studies (Majouga et al., 2014), where we observed poten-
tials around 0.45 V for the copper complexes of 2-
thiohydantoin. The facile reduction of these complexes wouldle-4-one complexes of copper(II) and cobalt(II): Synthesis, structural character-
1016/j.arabjc.2016.04.013
Table 4 Cytotoxicity of ligands and complexes against A549, MCF7 and HEK293T cell lines measured by MTT-assay (lM).a
Compound A549, lM MCF7, lM HEK293T, lM
1 >200 >200 111.41 ± 40.59
1a 45.94 ± 6.5 32.3 ± 9.4 19.85 ± 6.35
1b >200 131.04 ± 32.57 >200
2 >200 97.25 ± 19.56 183.20 ± 48.00
2a >60 84.25 ± 11.4 36.41 ± 10.16
2b >200 139.26 ± 48.05 126.74 ± 30.36
3 >200 >200 151.10 ± 36.50
3a 57.81 ± 0.55 45.13 ± 0.04 29.39 ± 14.04
3b 168.30 ± 31.30 140.40 ± 38.10 108.25 ± 17.25
5 >200 >200 167.32 ± 81.09
5a 19.00 ± 5.11 15.88 ± 0.14 7.98 ± 1.87
5b 119.80 ± 16.50 122.02 ± 38.39 121.0 ± 40.0
6 >200 >200 155.55 ± 43.65
6a 32.57 ± 3.99 22.00 ± 3.91 10.58 ± 1.15
6b 127.30 ± 17.90 87.28 ± 22.33 81.41 ± 12.10
7 >200 >200 111.41 ± 40.59
7a 18.27 ± 1.42 13.67 ± 0.81 6.20 ± 0.33
7b 137.95 ± 28.35 46.82 ± 13.63 117.96 ± 35.85
Doxorubicinb 2.0 ± 0.8 2.1 ± 0.8 1.1 ± 0.1
Cisplatinb >30 64.13 ± 3.9 12.4 ± 3.9
CuCl22H2Oc >100
a CuCl22H2O and CoCl26H2O have IC50 more than 100 lM on the cell line Hek293T (the most sensitive cell line in our tests).
b Majouga et al. (2014)
c Zhong et al. (2015).
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Figure 5 CVA for copper complex 1a on GC (left) and Au (right) electrodes (103 M, DMF, Bu4NClO4).
10 O.O. Krasnovskaya et al.facilitate their interaction with oxygen, which would enhance
their cytotoxicity. However, this outcome was not observed,
which suggested that the complexes prepared in the current
study exert their cytotoxicity through a different mechanism.
4. Conclusions
In conclusion, we have prepared a novel series of nitrogen-containing
bidentate organic ligands, together with their corresponding copper
and cobalt complexes. These compounds have been fully characterized
based on their NMR, IR, UV/Vis, elemental analysis and cyclic
voltammetry data. Three cobalt complexes were also characterizedPlease cite this article in press as: Krasnovskaya, O.O. et al., Novel 2-aminoimidazo
ization and cytotoxicity. Arabian Journal of Chemistry (2016), http://dx.doi.org/10.by single-crystal X-ray analysis. The cytotoxicities of the copper con-
taining complexes were comparable to those of cisplatin and doxoru-
bicin against MCF-7, A549 and HEK293 cells. In contrast to many
of other well-known metal-containing drugs, the mechanism of
action of these complexes does not appear to include the formation
of ROS.
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